Table of Contents Author Guidelines Submit a Manuscript
Journal of Biomedicine and Biotechnology
Volume 2010, Article ID 548749, 11 pages
http://dx.doi.org/10.1155/2010/548749
Research Article

A Styrene-alt-Maleic Acid Copolymer Is an Effective Inhibitor of R5 and X4 Human Immunodeficiency Virus Type 1 Infection

1Department of Microbiology and Immunology and Center for Molecular Therapeutics and Resistance, Center for Sexually Transmitted Disease, Institute for Molecular Medicine and Infectious Disease, Drexel University College of Medicine, 245 N. 15th Street (MS1013A), Philadelphia, PA 19102, USA
2Novaflux Biosciences, Inc., 1 Wall Street, Princeton, NJ 08540, USA

Received 7 January 2010; Accepted 11 March 2010

Academic Editor: Robert Blumenthal

Copyright © 2010 Vanessa Pirrone et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. Mitsuya, D. J. Looney, S. Kuno, R. Ueno, F. Wong-Staal, and S. Broder, “Dextran sulfate suppression of viruses in the HIV family: inhibition of virion binding to CD4+ cells,” Science, vol. 240, no. 4852, pp. 646–649, 1988. View at Google Scholar · View at Scopus
  2. M. Ito, M. Baba, A. Sato, R. Pauwels, E. De Clercq, and S. Shigeta, “Inhibitory effect of dextran sulfate and heparin on the replication of human immunodeficiency virus (HIV) in vitro,” Antiviral Research, vol. 7, no. 6, pp. 361–367, 1987. View at Google Scholar · View at Scopus
  3. M. Baba, R. Pauwels, J. Balzarini, J. Arnout, J. Desmyter, and E. De Clercq, “Mechanism of inhibitory effect of dextran sulfate and heparin on replication of human immunodeficiency virus in vitro,” Proceedings of the National Academy of Sciences of the United States of America, vol. 85, no. 16, pp. 6132–6136, 1988. View at Google Scholar · View at Scopus
  4. A. R. Neurath, N. Strick, Y. Y. Li, and A. K. Debnath, “Cellulose acetate phthalate, a common pharmaceutical excipient, inactivates HIV-1 and blocks the coreceptor binding site on the virus envelope glycoprotein gp120,” BMC Infectious Diseases, vol. 1, no. 1, article 17, 2001. View at Google Scholar · View at Scopus
  5. L. N. Callahan, M. Phelan, M. Mallinson, and M. A. Norcross, “Dextran sulfate blocks antibody binding to the principal neutralizing domain of human immunodeficiency virus type 1 without interferon with gp120-CD4 interactions,” Journal of Virology, vol. 65, no. 3, pp. 1543–1550, 1991. View at Google Scholar · View at Scopus
  6. M. Moulard, H. Lortat-Jacob, I. Mondor et al., “Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120,” Journal of Virology, vol. 74, no. 4, pp. 1948–1960, 2000. View at Publisher · View at Google Scholar · View at Scopus
  7. J. Balzarini and L. Van Damme, “Microbicide drug candidates to prevent HIV infection,” The Lancet, vol. 369, no. 9563, pp. 787–797, 2007. View at Google Scholar
  8. M. M. Lederman, R. E. Offord, and O. Hartley, “Microbicides and other topical strategies to prevent vaginal transmission of HIV,” Nature Reviews Immunology, vol. 6, no. 5, pp. 371–382, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Rusconi, M. Moonis, D. P. Merrill et al., “Naphthalene sulfonate polymers with CD4-blocking and anti-human immunodeficiency virus type 1 activities,” Antimicrobial Agents and Chemotherapy, vol. 40, no. 1, pp. 234–236, 1996. View at Google Scholar · View at Scopus
  10. P. Mohan, D. Schols, M. Baba, and E. De Clercq, “Sulfonic acid polymers as a new class of human immunodeficiency virus inhibitors,” Antiviral Research, vol. 18, no. 2, pp. 139–150, 1992. View at Publisher · View at Google Scholar · View at Scopus
  11. R. F. Rando, S. Obara, M. C. Osterling et al., “Critical design features of phenyl carboxylate-containing polymer microbicides,” Antimicrobial Agents and Chemotherapy, vol. 50, no. 9, pp. 3081–3089, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. P. J. Klasse, R. Shattock, and J. P. Moore, “Antiretroviral drug-based microbicides to prevent HIV-1 sexual transmission,” Annual Review of Medicine, vol. 59, pp. 455–471, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Konlee, “Sulfated polysaccharides (chondroitin sulfate and carrageenan) plus glucosamine sulfate are potent inhibitors of HIV,” Positive Health News, no. 17, pp. 4–7, 1998. View at Google Scholar · View at Scopus
  14. P. Charneau, G. Mirambeau, P. Roux, S. Paulous, H. Buc, and F. Clavel, “HIV-1 reverse transcription. A termination step at the center of the genome,” Journal of Molecular Biology, vol. 241, no. 5, pp. 651–662, 1994. View at Publisher · View at Google Scholar · View at Scopus
  15. E. J. Platt, K. Wehrly, S. E. Kuhmann, B. Chesebro, and D. Kabat, “Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1,” Journal of Virology, vol. 72, no. 4, pp. 2855–2864, 1998. View at Google Scholar · View at Scopus
  16. H.-W. Lahm and S. Stein, “Characterization of recombinant human interleukin-2 with micromethods,” Journal of Chromatography, vol. 326, pp. 357–361, 1985. View at Google Scholar · View at Scopus
  17. B. K. Brown, J. M. Darden, S. Tovanabutra et al., “Biologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 isolates, representing clades A, B, C, D, CRF01_AE, and CRF02_AG, for the development and assessment of candidate vaccines,” Journal of Virology, vol. 79, no. 10, pp. 6089–6101, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. L. L. Jagodzinski, D. L. Wiggins, J. L. McManis et al., “Use of calibrated viral load standards for group M subtypes of human immunodeficiency virus type 1 to assess the performance of viral RNA quantitation tests,” Journal of Clinical Microbiology, vol. 38, no. 3, pp. 1247–1249, 2000. View at Google Scholar · View at Scopus
  19. N. L. Michael, S. A. Herman, S. Kwok et al., “Development of calibrated viral load standards for group M subtypes of human immunodeficiency virus type 1 and performance of an improved AMPLICOR HIV-1 MONITOR test with isolates of diverse subtypes,” Journal of Clinical Microbiology, vol. 37, no. 8, pp. 2557–2563, 1999. View at Google Scholar · View at Scopus
  20. M. Vahey, M. E. Nau, S. Barrick et al., “Performance of the Affymetrix GeneChip HIV PRT 440 platform for antiretroviral drug resistance genotyping of human immunodeficiency virus type 1 clades and viral isolates with length polymorphisms,” Journal of Clinical Microbiology, vol. 37, no. 8, pp. 2533–2537, 1999. View at Google Scholar · View at Scopus
  21. F. C. Krebs, S. R. Miller, D. Malamud, M. K. Howett, and B. Wigdahl, “Inactivation of human immunodeficiency virus type 1 by nonoxynol-9, C31G, or an alkyl sulfate, sodium dodecyl sulfate,” Antiviral Research, vol. 43, no. 3, pp. 157–173, 1999. View at Google Scholar · View at Scopus
  22. T. Mosmann, “Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays,” Journal of Immunological Methods, vol. 65, no. 1-2, pp. 55–63, 1983. View at Google Scholar · View at Scopus
  23. A. H. Cory, T. C. Owen, J. A. Barltrop, and J. G. Cory, “Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture,” Cancer Communications, vol. 3, no. 7, pp. 207–212, 1991. View at Google Scholar · View at Scopus
  24. B. J. Catalone, S. R. Miller, M. L. Ferguson et al., “Toxicity, inflammation, and anti-human immunodeficiency virus type 1 activity following exposure to chemical moieties of C31G,” Biomedicine and Pharmacotherapy, vol. 59, no. 8, pp. 430–437, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. J. P. Moore, S. G. Kitchen, P. Pugach, and J. A. Zack, “The CCR5 and CXCR4 coreceptors—central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection,” AIDS Research and Human Retroviruses, vol. 20, no. 1, pp. 111–126, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. I. A. Scordi-Bello, A. Mosoian, C. He et al., “Candidate sulfonated and sulfated topical microbicides: comparison of anti-human immunodeficiency virus activities and mechanisms of action,” Antimicrobial Agents and Chemotherapy, vol. 49, no. 9, pp. 3607–3615, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. X. Tan, R. Pearce-Pratt, and D. M. Phillips, “Productive infection of a cervical epithelial cell line with human immunodeficiency virus: implications for sexual transmission,” Journal of Virology, vol. 67, no. 11, pp. 6447–6452, 1993. View at Google Scholar · View at Scopus
  28. O. Bagasra and H. W. Lischner, “Activity of dextran sulfate and other polyanionic polysaccharides against human immunodeficiency virus,” Journal of Infectious Diseases, vol. 158, no. 5, pp. 1084–1087, 1988. View at Google Scholar · View at Scopus
  29. A. de Parseval, M. D. Bobardt, A. Chatterji et al., “A highly conserved arginine in gp120 governs HIV-1 binding to both syndecans and CCR5 via sulfated motifs,” Journal of Biological Chemistry, vol. 280, no. 47, pp. 39493–39504, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. H. A. Harrop, D. R. Coombe, and C. C. Rider, “Heparin specifically inhibits binding of V3 loop antibodies to HIV-1 gp120, an effect potentiated by CD4 binding,” AIDS, vol. 8, no. 2, pp. 183–192, 1994. View at Google Scholar · View at Scopus
  31. H. A. Harrop and C. C. Rider, “Heparin and its derivatives bind to HIV-1 recombinant envelope glycoproteins, rather than to recombinant HIV-1 receptor, CD4,” Glycobiology, vol. 8, no. 2, pp. 131–137, 1998. View at Publisher · View at Google Scholar · View at Scopus
  32. M. O. McClure, J. P. Moore, D. F. Blanc et al., “Investigations into the mechanism by which sulfated polysaccharides inhibit HIV infection in vitro,” AIDS Research and Human Retroviruses, vol. 8, no. 1, pp. 19–26, 1992. View at Google Scholar · View at Scopus
  33. R. R. Vives, A. Imberty, Q. J. Sattentau, and H. Lortat-Jacob, “Heparan sulfate targets the HIV-1 envelope glycoprotein gp120 coreceptor binding site,” Journal of Biological Chemistry, vol. 280, no. 22, pp. 21353–21357, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. J. Qian, S. Miller, M. L. Ferguson et al., “Use of the synthetic copolymer PSMA as a component in a combination microbicide active against HIV-1,” Retrovirology, vol. 2, supplement 1, p. S96, 2005. View at Google Scholar
  35. W. Fang, Y. Cai, X. Chen et al., “Poly(styrene-alt-maleic anhydride) derivatives as potent anti-HIV microbicide candidates,” Bioorganic and Medicinal Chemistry Letters, vol. 19, no. 7, pp. 1903–1907, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. W. Tao, C. Richards, and D. Hamer, “Enhancement of HIV infection by cellulose sulfate,” AIDS Research and Human Retroviruses, vol. 24, no. 7, pp. 925–929, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. R. F. Tsuji, K. Hoshino, Y. Noro et al., “Suppression of allergic reaction by ?-carrageenan: toll-like receptor 4/MyD88-dependent and -independent modulation of immunity,” Clinical and Experimental Allergy, vol. 33, no. 2, pp. 249–258, 2003. View at Publisher · View at Google Scholar · View at Scopus
  38. R. J. Pomerantz, M. B. Feinberg, D. Trono, and D. Baltimore, “Lipopolysaccharide is a potent monocyte/macrophage-specific stimulator of human immunodeficiency virus type 1 expression,” Journal of Experimental Medicine, vol. 172, no. 1, pp. 253–261, 1990. View at Publisher · View at Google Scholar · View at Scopus
  39. V. Halpern, F. Ogunsola, O. Obunge et al., “Effectiveness of cellulose sulfate vaginal gel for the prevention of HIV infection: results of a phase III trial in Nigeria,” PLoS ONE, vol. 3, no. 11, article e3784, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. L. Van Damme, R. Govinden, F. M. Mirembe et al., “Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission,” The New England Journal of Medicine, vol. 359, no. 5, pp. 463–472, 2008. View at Google Scholar
  41. I. M. Malonza, F. Mirembe, C. Nakabiito et al., “Expanded Phase I safety and acceptability study of 6% cellulose sulfate vaginal gel,” AIDS, vol. 19, no. 18, pp. 2157–2163, 2005. View at Google Scholar
  42. C. Mauck, D. H. Weiner, S. Ballagh et al., “Single and multiple exposure tolerance study of cellulose sulfate gel: a Phase I safety and colposcopy study,” Contraception, vol. 64, no. 6, pp. 383–391, 2001. View at Publisher · View at Google Scholar · View at Scopus
  43. A. R. Neurath, N. Strick, and Y. Y. Li, “Role of seminal plasma in the anti-HIV-1 activity of candidate microbicides,” BMC Infectious Diseases, vol. 6, article 150, 2006. View at Google Scholar
  44. V. Pirrone, S. R. Passic, B. Wigdahl, and F. C. Krebs, “Clinical failures of select polyanionic microbicide candidates may be predicted by in vitro enhancement of HIV-1 infection,” in Proceedings of the 22nd International Conference on Antiviral Research, Miami, Fla, USA, 2009.
  45. C. Flexner, P. A. Barditch-Crovo, D. M. Kornhauser et al., “Pharmacokinetics, toxicity, and activity of intravenous dextran sulfate in human immunodeficiency virus infection,” Antimicrobial Agents and Chemotherapy, vol. 35, no. 12, pp. 2544–2550, 1991. View at Google Scholar
  46. J. Horwood, “Cellulose sulphate microbicide trial halted,” The Lancet Infectious Diseases, vol. 7, no. 3, p. 183, 2007. View at Google Scholar
  47. J. Cohen, “AIDS research: microbicide fails to protect against HIV,” Science, vol. 319, no. 5866, pp. 1026–1027, 2008. View at Google Scholar · View at Scopus
  48. J. Cohen, “HIV Outwits Yet Another Microbicide,” ScienceNOW Daily News, December 2009, http://news.sciencemag.org/sciencenow/2009/12/14-01.html.
  49. M. Warren and K. Marshall, “AVAC says MDP 301 Microbicide Trial results Disappointing, But Researchers and 9,400 Trial Volunteers Deserve Praise for Successful Trial,” AVAC Global Advocacy for HIV Prevention, December 2009.